Get the Stockscreener App
250.80
0.95%
-2.40
After Hours:
250.80
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $250.80, with a volume of 909.60K.
It is down -0.95% in the last 24 hours and up +12.97% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$253.20
Open:
$250.33
24h Volume:
909.60K
Relative Volume:
0.73
Market Cap:
$35.27B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
24.18
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
+2.16%
1M Performance:
+12.97%
6M Performance:
+12.96%
1Y Performance:
-3.24%
1-Day Range:
$247.70
$251.76
1-Week Range:
$244.18
$255.56
52-Week Range:
$180.26
$277.67
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
250.80 | 35.27B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
445.88 | 157.52B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
195.03 | 53.12B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
69.42 | 33.56B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
32.38 | 28.41B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-19-26 | Initiated | Rothschild & Co Redburn | Neutral |
| Jul-16-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-13-26 | Downgrade | Citigroup | Buy → Neutral |
| Jun-17-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
ResMed Inc. (RMD) options chain - Yahoo Finance Australia
ResMed Inc. (RMD) Stock Forecasts - Yahoo! Finance Canada
ResMed Inc. (RMD) Stock Forecasts - Yahoo! Finance Canada
Form 144 RESMED INC For: 23 October By Investing.com - Investing.com South Africa
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
ResMed Inc. Estimates – NYSE:RMD - TradingView
ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock? - Zacks Investment Research
ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock? - Yahoo Finance
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance Singapore
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
ResMed Inc. (RMD) Stock Forecasts - Yahoo! Finance Canada
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
ResMed Converts Physician Loyalty Into Pricing Power - Morningstar
ResMed's 18% Rally Meets A Thin Quarter As Astral And Margin Pressure Weigh - Finviz
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
ResMed Price Target Raised 3.6% to US$233.00/Share by Morgan Stanley - Moomoo
ResMed back to Hold - www.intelligentinvestor.com.au
Goodman, Pro Medicus and ResMed FY26 Results: Growth Drivers and FY27 Outlook - Kalkine
Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.
ResMed Inc. (NYSE:RMD) Stock Now Rated "Hold" by Sell-Side Analysts - MarketBeat
ResMed Inc. (ASX:RMD): Operations, Earnings and Business Priorities - Kalkine
Resmed Launches AirTouch F40 Full Face Fabric CPAP Mask in US - HomeCare
ETFs Are Net Sellers of ResMed (RMD) on Oct. 16 - Yahoo Finance
Resmed Inc (ASX:RMD) Expands Sleep Therapy Portfolio Following Fiscal Results - Kalkine
What Does ResMed’s (ASX:RMD) Latest Annual Report Mean for Investors? - Kalkine
ResMed to Launch AirTouch F40 Sleep Apnea Mask - marketscreener.com
Resmed, Inc. Launches AirTouch F40 Full Face Fabric CPAP Mask In The US - www.marketscreener.com
Form 4 ResMed Inc: Aaron Bloomer (CFO) For: 14 August By Investing.com - Investing.com South Africa
A fabric sleep apnea mask is designed to fit 96% of people. Resmed says it will be available in the U.S. Oct. 28. - Stock Titan
Form 4 ResMed Inc: Aaron Bloomer (CFO) For: 14 August By Investing.com - Investing.com UK
Form 4 ResMed Inc: Justin Leong (Chief Product Officer) For: 14 August - Investing.com UK
ResMed Inc. (RMD) Stock Forecasts - Yahoo! Finance Canada
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
ResMed Inc. (RMD) Stock Forecasts - Yahoo! Finance Canada
ResMed (NYSE:RMD) Share Price Crosses Above 50 Day Moving AverageShould You Sell? - MarketBeat
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed’s Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
Mizuho Adjusts Price Target on ResMed to $240 From $235 - www.marketscreener.com
EBITDA of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA - TradingView
ResMed Q4 2026 Earnings Call Transcript - Benzinga
Is ResMed Facing Fresh Questions Before Results (ASX:RMD)? - Kalkine Media
Form 144 RESMED INC For: 10 October By Investing.com - Investing.com South Africa
Form 144 RESMED INC For: 10 October By Investing.com - Investing.com Nigeria
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Resmed Inc Stock (RMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rider Michael J | Officer |
Oct 23 '26 |
Proposed Sale |
255.00 |
400 |
102,000 |
0 |
| Farrell Michael J. | Officer |
Oct 07 '26 |
Proposed Sale |
226.33 |
4,991 |
1,129,638 |
0 |
| Farrell Michael J. | Chairman and CEO |
Oct 07 '26 |
Sale |
226.33 |
4,991 |
1,129,637 |
479,803 |
| Farrell Michael J. | Chairman and CEO |
Oct 07 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
484,794 |
| Farrell Michael J. | Chairman and CEO |
Sep 08 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
471,247 |
| Farrell Michael J. | Chairman and CEO |
Sep 08 '26 |
Sale |
222.44 |
4,991 |
1,110,191 |
466,256 |
| Farrell Michael J. | Officer |
Sep 08 '26 |
Proposed Sale |
226.22 |
4,991 |
1,129,064 |
0 |
| FARRELL PETER C | Director |
Sep 02 '26 |
Sale |
234.73 |
970 |
227,688 |
51,803 |
| Peter C Farrell | Director |
Sep 02 '26 |
Proposed Sale |
234.65 |
970 |
227,608 |
0 |
| Farrell Michael J. | Chairman and CEO |
Aug 07 '26 |
Option Exercise |
146.34 |
4,991 |
730,383 |
471,247 |
0.81%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):